20th International Pharmacovigilance Training Course

21 May - 1 June 2018
Uppsala, Sweden
UMC is at the forefront of seeking advances in the safety and well-being of patients by identifying the benefits and risks of medicines – so that, globally, patients and health professionals can make wise therapeutic decisions.

The purpose of the course is to further develop effective and sustainable pharmacovigilance in all countries by creating a unique opportunity for learning and collaboration.

Participants will acquire the theoretical as well as practical knowledge and skills essential to initiate or develop pharmacovigilance plans in their own countries. Close interaction among participants will also provide an ideal forum for building important relationships at local, regional and global levels to stimulate change in pharmacovigilance.

Course outline
The course focuses on topics essential to effective pharmacovigilance, including sessions to strengthen the WHO Programme for International Drug Monitoring, e.g. pharmacovigilance best practices, communications, creating a reporting culture and pharmacovigilance tools.

The course agenda also includes extensive workshops in hands-on signal detection and causality assessment as well as vaccine safety and pharmacoepidemiology.

Training, built around lectures, workshops and practical exercises, takes place in an open and interactive environment.

Plenty of opportunities to interact with UMC staff, faculty experts and fellow course participants will be provided. Social activities and events include an official course dinner and ‘open house’ at the UMC office.

Faculty
International pharmacovigilance experts from the WHO Headquarters, WHO Collaborating Centres, UMC and other well-known organizations will lead the sessions.

Interested?
This two-week course is tailored for representatives of national pharmacovigilance centres and ministries of health but is also suitable for representatives of public health programmes and healthcare professionals, e.g. physicians, pharmacists, nurses) from hospitals or academic settings. Participants are expected to actively contribute to discussions in English and have experience in the pharmacovigilance field.

How to apply
The goal of UMC’s admissions review process is to select individuals committed to patient safety who can contribute actively during these two weeks. All participants will be given access to pre–course reading materials. We encourage you to start the application process as soon as possible; the course is designed for a maximum of 30 people.

Please submit your application via the electronic form available on the UMC website (www.who-umc.org) by January 12th, 2018.

Cost
The course fee is 33,000 SEK (VAT included) for public/academic sector representatives and 58,000 SEK (VAT included) for industry sector representatives. This fee includes accommodation, breakfast, lunches during course days, course material and social activities. Airfares, per diem, health insurance and all other associated costs are the responsibility of each participant or sponsoring organization.

Venue
The course takes place in the city of Uppsala, which lies in the heart of Sweden just 70 km from Stockholm and 35 km from Arlanda International Airport. Uppsala is Sweden’s fourth largest city and home to over 200,000 people. It has retained its small-town charm yet offers a big city’s selection of shops, restaurants and things to do. This vibrant city also hosts the oldest centre of higher education in Scandinavia, Uppsala University, founded in 1477.

Questions
If you have questions, please visit our website: www.who-umc.org
or contact the course management via e-mail: pvtraining@who-umc.org

We look forward to welcoming you to Uppsala!
About Uppsala Monitoring Centre

Uppsala Monitoring Centre (UMC) advances the science of pharmacovigilance and inspires patient safety initiatives all over the world.

As an independent, non-profit foundation, UMC engages stakeholders who share their vision and collaborates to build a global patient safety culture. As a leader in the research and development of new scientific methods, UMC explores the benefits and risks of medicines to help minimise harm to patients, and offers products and services used by health authorities and life-science companies worldwide. For almost 40 years, UMC has provided scientific leadership and operational support to the WHO Programme for International Drug Monitoring.